Gå til innholdet
Menu

PHARMAQ's PD vaccine prevails before the Supreme Court

- Outright victory at the Supreme Court

Oslo,
5th of April 2017

• In 2014, MSD obtained a supplementary protection certificate which effectively extended the term of their patent covering PD vaccines and prevented other suppliers from gaining access to the market to 2020
• The Norwegian Supreme Court has now decided that MSD had no legal right to such a monopoly and the certificate has been revoked
• The decision means that other suppliers are now able to offer alternative vaccines against PD

On the 4th of April 2017, the decision by the Supreme Court upheld PHARMAQ's argument that the supplementary protection certificate effectively extending the term of the patent should not have been awarded to MSD.

In its ruling, the Norwegian Appeals Court considered the comparative efficacy and stated that "[t]he Court of Appeal's overall assessment of the research data presented and the other evidence is that there are significant differences in vaccine efficacy, and that PHARMAQ's vaccine in actual practice has a significantly better effect against SAV-3 infection than Intervet's vaccine. The differences are consistent and systematic".

If the Norwegian and global aquaculture sectors are to operate sustainably, they need product variation and choice. Since 2004, PHARMAQ has contributed to this by measures such as the launch of 28 vaccines providing protection against a broad range of diseases, and which have made it possible to almost eliminate the use of antibiotics in the Norwegian aquaculture industry.

PHARMAQ has been prevented from launching its own PD vaccine because of the MSD monopoly, and is now looking forward to obtaining market access for the vaccine which has been ready for some time. It will provide the Norwegian aquaculture sector with an effective alternative in its fight against PD.

"This decision is no surprise, we always knew our vaccine was significantly more effective for pancreatic disease in Salmon in Norway and we are pleased that the Supreme Court has confirmed the decision from the Appeal Court and denied MSD the supplementary protection certificate", says PHARMAQ President Morten Nordstad.

For further information, please contact:
Morten Nordstad, President, PHARMAQ – a business of Zoetis
Telephone: +47 23 29 85 10
Mobile: +47 907 52 853

About PHARMAQ
PHARMAQ is the global leader in vaccines and innovation for aquaculture and part of Zoetis, the world leader in animal health. The company provides environmentally sound, safe and efficacious health products to the global aquaculture industry through targeted research and the commitment of dedicated people. Production facilities, administration and research and development activities are based in Norway with subsidiaries in Chile, United Kingdom, China, Vietnam, Turkey, Spain, Panama and Singapore. PHARMAQ has approximately 220 employees. The company's products are marketed in Europe, North and South America, and Asia. For further information, visit the company's website at www.pharmaq.com

Did you know...

WE MAKE AQUACULTURE PROGRESS

Newsfeed delivered by Meltwater News. PHARMAQ is not to be held liable for any of its content nor possible incorrect information given.

»
»
»
»
»
»
»
»
»
»

Norway

PHARMAQ AS
Head office/
Production facility
Skogmo Industriområde
Industrivegen 50
N-7863 Overhalla, Norway
Tel:+47 74 28 08 00
customer.service​@pharmaq.no


PHARMAQ AS
Production facility
Dyrskuevien 13, 2040 Kløfta
P.O.Box 152, N-2041 Kløfta, Norway
Tel: +47 23 29 85 00
customer.service​@pharmaq.no

   

PHARMAQ AS
Harbitzalléen 2A, 0275 Oslo
P.O.Box 267 Skøyen
N-0213 Oslo, Norway
Tel: +47 23 29 85 00
customer.service​@pharmaq.no

   

PHARMAQ Analytiq
Thormøhlensgate 53D
N-5008 Bergen, Norway
Tel: (+47) 23 29 85 00
kontakt@analytiq.no

   

PHARMAQ Fishteq
Havneveien 6
N-8700 Nesna, Norway
Tel:+47 941 63 150
PHQ.fishteqsupport@zoetis.com

Chile

PHARMAQ AS Chile Ltda.
Bernardino # 1981, Piso 2, Oficina 202,
Parque Empresarial San Andrés,
Puerto Montt, Chile
Tel: +56 65 248 3091
customer.service​@pharmaq.no

 

United Kingdom

PHARMAQ Ltd.
Unit 15 Sandleheath Industrial Estate,
Fordingbridge,
Hampshire SP6 1PA,
United Kingdom
Tel: +44 1425 656081
orders@pharmaq.no

Terms & Conditions of Purchase
Terms & Conditions of Sale
Tax strategy and Disclosure: Financial year ending 30 November 2017

Turkey

PHARMAQ Veteriner Ecza Deposu ve Su Ürünleri Tic.Ltd.Şti
KARACAOGLAN MAH. 6166 SK. 21 A BORNOVA/ IZMIR Turkiye
Tel: +90 232 422 23 10
customer.service​@pharmaq.no

Vietnam

PHARMAQ Ltd. VN
R. 2503, 25th Fl., Viettel Tower
285 Cach Mang Thang Tom
W.12, D10, HCMC, Vietnam
Tel : +84 28 6284 5350
customer.service​@pharmaq.no

Panama

Zoetis Panamá / PHARMAQ Panamá
Piso 2. Oficina 108. P.H. Albrook Commercial Park
Ave. Bella Vista, Ancón, Panamá
PO. Box: 0832-0588
Phone: +507 3215363
Mob.: +507 6675 1109
customer.service​@pharmaq.no

Spain

PHARMAQ Spain Aqua
Avda de Europa 20B
Parque Empresarial La Moraleja
28108 Alcobendas, Spain
Tel: +34 91 419 19 35
customer.service​@pharmaq.no

Singapore

PHARMAQ part of Zoetis
108 Pasir Panjang Road
Singapore 118535, Singapore
Tel.: +65 6933 5800
customer.service​@pharmaq.no

PHARMAQ is the global leader in vaccines and innovation for aquaculture and part of Zoetis, the world leader in animal health. The company provides environmentally sound, safe and efficacious health products to the global aquaculture industry through targeted research and the commitment of dedicated people. Production facilities, administration and research and development activities are based in Norway with subsidiaries in Chile, United Kingdom, Vietnam, Turkey, Spain, Panama and Hong Kong. PHARMAQ has approximately 300 employees. The company's products are marketed in Europe, North and South America, and Asia. For further information, visit the company's website at www.pharmaq.comPrivacy Policy. Cookie Policy. Terms of Use.

Copyright © 2016 Zoetis LLC. All rights reserved.

Utviklet av Imaker as